Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP5 | Q96HI0 | 14/20 | 0.59 |
| ▸ | SENP2 | Q9HC62 | 14/20 | 0.59 |
| ▸ | SENP1 | Q9P0U3 | 14/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633875 | 0.87 | ALDH1A1 (0.67) | SENP5SENP2SENP1USP2LMNA | |
| SCHEMBL17149276 | 0.86 | SENP5 (0.52) | SENP5SENP2SENP1USP2LMNA | |
| SCHEMBL4634988 | 0.86 | SENP2 (0.54) | SENP5SENP2SENP1USP2LMNA | |
| SCHEMBL4634951 | 0.86 | KDM4E (0.67) | SENP5SENP2SENP1USP2KDM4E | |
| SCHEMBL15697530 | 0.85 | LMNA (0.61) | SENP5SENP2SENP1LMNAMAPK1 | |
| SCHEMBL4604049 | 0.84 | SENP2 (0.53) | SENP5SENP2SENP1USP2LMNA | |
| SCHEMBL9595149 | 0.83 | SENP2 (0.56) | SENP5SENP2SENP1USP2KDM4E | |
| SCHEMBL1745439 | 0.83 | LMNA (0.60) | LMNAMAPK1KDM4EHPGDGAA | |
| SCHEMBL8913166 | 0.83 | LMNA (0.60) | LMNAMAPK1KDM4EHPGDGAA | |
| SCHEMBL4634996 | 0.83 | KMT2A (0.64) | SENP5SENP2SENP1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150282482-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| EP-1585745-A4 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | TRILLIUM THERAPEUTICS INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | SENP5 3396/4885SENP2 4265/4885SENP1 4469/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | SENP5 3396/4885SENP2 4265/4885SENP1 4469/4885 |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF2, BROX, BOLA2; BOLA2B | SENP5 2012/4885SENP2 2286/4885SENP1 3231/4885 |
| US-20150282482-A1 | METHOD FOR PROMOTING PLANT GROWTH | BOLA2; BOLA2B, BROX, TET1 | SENP5 2576/4885SENP2 2743/4885SENP1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.